Accuray, Inc. (ARAY)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.27+0.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · ARAY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue executing the multi-phase transformation plan focused on cost reduction, margin improvement, and operational efficiency.
Stated as a priority in 3 of last 3 quarters. The transformation plan delivered over $20 million in cost and margin improvements in fiscal 2026, surpassing the original $12 million target. Operating expenses decreased slightly despite restructuring charges. Management is delivering on cost and margin improvement commitments.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company’s transformation plan delivered more than $20 million of cost and margin improvement during fiscal 2026.”
“Transformation plan delivering ahead of expectations, with approximately $10 million of cost and margin improvements achieved through the fiscal third quarter.”
“We continued to expand service revenue, improve operating efficiency, and execute our transformation initiatives ahead of expectations.”
Enhance liquidity, reduce leverage, and improve financial flexibility through agreements with TCW Asset Management.
Stated as a priority in 2 disclosures including 2026-Q4. The TCW agreements include a $40 million debt-for-equity exchange, $15 million cash investment, and covenant relief through December 2027. These actions materially strengthen liquidity and financial flexibility, matching management’s stated objectives.
“Announced a comprehensive financing transaction with TCW Asset Management that strengthens liquidity and reduces leverage.”
Develop collaborations with leading technology companies to enhance capabilities and accelerate innovation.
Stated as a priority in 3 disclosures including 2026-Q4 and 2026-Q3. Management highlights expanding partnerships with Samsung, RaySearch, and TCS to accelerate innovation and improve operational performance. While no specific revenue impact is cited yet, the partnerships are progressing as planned.
“Expanding strategic partnership ecosystem through collaborations with leading organizations.”
“Strategic partnerships gaining momentum, expanding Accuray’s ecosystem across imaging, software, workflow, and clinical research.”
Enhance commercial organization and execution capabilities to drive sales growth and market penetration.
Stated as a priority in 2 disclosures including 2026-Q3. The appointment of Paul Miele as Chief Commercial Officer aims to strengthen commercial execution and accelerate sales growth. While revenue declined in fiscal 2026, management emphasizes ongoing efforts to improve commercial performance.
“Commercial leadership strengthened with appointment of Paul Miele as Chief Commercial Officer.”
Suspend financial guidance for fiscal 2026 amid geopolitical uncertainty impacting product shipments and installations.
Stated as a priority in 2 consecutive quarters. Management withdrew fiscal 2026 guidance in 2026-Q3 due to geopolitical uncertainty impacting shipments and installations, and continued withholding formal guidance for fiscal 2027 in 2026-Q4. This reflects ongoing caution amid external risks.
“Given ongoing uncertainty related to geopolitical developments, the Company is not providing formal revenue or Adjusted EBITDA guidance for fiscal 2027 at this time.”
“Company withdraws fiscal 2026 financial guidance due to geopolitical uncertainty in the Middle East.”
Over the trailing year it converted -0.52x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
28 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.